
Who's online
There are currently 8 users and 269 guests online.
Online users
- Moon
- Sahithya
- machyman
- Sysadmin
- Dan Meshak
- DenisV
- ric.ataide
- nicoM
News Flash
Recent blog posts
- Where the real battle is won
- Amazing statements by leading malariologists
- How was malaria of 100 years ago eradicated in Palestine/Israel? And without vaccine?
- Winston Hide's courageous move
- Event: Symposium Malaria, maternal and infant health
- Job: Senior Lecturer / Lecturer in Epidemiology
- Job: Inspiring scientists in infectious tropical diseases
- Can we maintain effectiveness of the tools?
- Advertising on MalariaWorld
- Malaria elimination country briefings published by the UCSF Global Health Group
Active forum topics
- The role of community education and involvement in malaria control
- Introduce yourself to MalariaWorld members
- Fighting drug resistance by switching to environmental management of mosquito habitats
- Need for additional group to supplement WHO in fight against malaria
- Sustainable additions to WHO and PMI strategy
New forum topics
- Fighting drug resistance by switching to environmental management of mosquito habitats
- Grand Challemges Canada round 2. Help fund a malaria related project!
- Open Access 2.0:How to achieve this
- Pouring gasoline on the insecticide resistance fire?
- Need for additional group to supplement WHO in fight against malaria
Specific human IgG responses to gSG6-P1 peptide biomarker represent, at the population and individual levels, a credible new alternative tool to assess accurately the heterogeneity of exposure level to Anopheles bites and malaria risk in low urban transmission areas.
The Research Center for Human Development in Dakar (CRDH) with the technical assistance of ICF Macro and the National Malaria Control Programme (NMCP) conducted in 2008/2009 the Senegal Malaria Indicator Survey (SMIS), the first nationally representative household survey collecting parasitological data and malaria-related indicators.
We conducted a study to assess malaria vector diversity, dynamics and malaria transmission in the area.
This study points to several strategies that may help bridge the gap between what is known from research evidence and the knowledge and practices of healthcare providers.
The introduction of ACT in 2002 has not induced a decrease in P. falciparum susceptibility to the drugs DHA, MDAQ and LMF, which are common ACT components. However, the prevalence of P. falciparum isolates with reduced susceptibility has increased for both MQ and DOX.
The transition from chloroquine to AQ+SP was well followed. Nonetheless, blood smear use was very low and many over-prescriptions were reported.
Collections were performed in two villages: Dielmo (Soudan savanna) and Bandafassi (Soudan Guinean savanna), two or three nights per month for a 4-5 months period during the maximal transmission season in 2001-2002.
Study results confirmed the satisfactory efficacy and safety profile of ASAQ and AL. Moreover, in patients who were treated at least twice, repeated administration of ASAQ or AL did not identify any major safety issues.
This study provides direct evidence of malaria risk receding between 1996-2010 and becoming equal throughout life where transmission used to be moderate.
